Abstract: A harmonic magnetic field driving electric motor, comprising: A. a stator lamination being provided with a plurality of tooth slots, Z; B. in a 360° mechanical space of the circumference of a stator, a stator winding being divided into m phases according to a set connection rule; C. a stator assembly having the winding being independently placed in a free space; D. wire packets contained in each phase of winding; E. permanent magnet rotor magnetic steel sequentially arranged in a circumferential direction according to the N-pole and S-pole sequence; F. in the 360° mechanical spaces of the circumferences of the stator and the rotor, an electric motor air gap in a combined space.

Abstract: The present disclosure provides an organic light-emitting diode, a display panel and a display device, relating to the field of display technologies. The organic light-emitting diode includes a first electrode, at least two emission layers, an optical modulation layer, and a second electrode. A thickness of the optical modulation layer has a relatively bigger range. Therefore, in the case that the thicknesses of other film layers between the first electrode and the second electrode vary, an optical modulation layer having a different thickness can be provided to adjust the microcavity length of the organic light-emitting diode, thereby ensuring the optical performance of the organic light-emitting diode and the display effect of the display panel.

Abstract: The present invention belongs to the fields of insecticides and acaricides, and particularly relates to a piperonylic acid derivative and application thereof. The structure is shown in a general formula I, and the definition of each substituent in the formula is described in the description. The compound of the general formula I has excellent insecticidal and acaricidal activity and can be used for controlling various pests and mites.

Abstract: The present invention discloses an oxime ether compound with novel structure. The structure is shown in general formula I. The definition of each substituent in the formula is provided in the description. The compound of general formula I has excellent microbicidal 1 activity, and has good control effects on plant bacterial diseases and fungal diseases. The present invention comprises an application of the compound of the general formula I as a microbicide in agriculture and other fields.

Abstract: Provided is an organic light-emitting diode, including a first electrode, a second electrode, at least two emission layers, a first hole transport layer and a second hole transport layer. A color of a mixture of light emitted from the at least two emission layers is white. The at least two emission layers includes a first emission layer and a second emission layer. The first electrode, the first emission layer, the first hole transport layer, the second hole transport layer, the second emission layer, and the second electrode are disposed on a base substrate and are sequentially laminated in a direction going away from the base substrate. A thickness of the second hole transport layer is greater than a first thickness threshold. A ratio of the thickness of the second hole transport layer to a thickness of the first hole transport layer ranges from 15 to 40.

Abstract: Provided is a display panel. The display panel includes a base substrate, a first electrode, a light-emitting layer, a protective layer, and a second electrode which are sequentially laminated on a side of the base substrate. A side of the light-emitting layer away from the base substrate is embedded with a target particle, and a gap in communication with the side of the light-emitting layer away from the base substrate is defined between the light-emitting layer and the target particle. The protective layer at least includes a first portion insulated from both the first electrode and the second electrode. The first portion fills the gap.

Abstract: Disclosed herein is an optogenetics-based gene therapy that involves channelrhodopsin fusion proteins having an inner mitochondrial membrane-mitochondrial localization signal (IMM-MLS) that can effectively target the fusion protein to an inner mitochondria membrane, and a channelrhodopsin ion channel domain that can change the mitochondrial membrane potential (??m) when light is present. The disclosed optogenetics-based gene therapy system can in some embodiments further involve luciferase fusion proteins to stimulate the channelrhodopsin without reliance on external light that has an outer mitochondrial membrane-mitochondrial localization signal (OMM-MLS) that can effectively target the luciferase fusion protein to an outer mitochondrial membrane, and a luciferase protein that can produce a bioluminescence in the presence of a luciferase substrate.

Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

Abstract: Compounds of formula Ia and Ib wherein A, B, C, R1 and R14 are described herein.

Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.